These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1443 related items for PubMed ID: 12538684

  • 1. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ.
    J Immunol; 2003 Feb 01; 170(3):1257-66. PubMed ID: 12538684
    [Abstract] [Full Text] [Related]

  • 2. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
    Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K.
    J Immunol; 2005 Aug 01; 175(3):1586-92. PubMed ID: 16034097
    [Abstract] [Full Text] [Related]

  • 3. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
    Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM.
    Eur J Immunol; 2002 Mar 01; 32(3):634-43. PubMed ID: 11857337
    [Abstract] [Full Text] [Related]

  • 4. Expression of programmed death 1 ligands by murine T cells and APC.
    Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H.
    J Immunol; 2002 Nov 15; 169(10):5538-45. PubMed ID: 12421930
    [Abstract] [Full Text] [Related]

  • 5. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
    Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, Honjo T.
    Immunol Lett; 2002 Oct 21; 84(1):57-62. PubMed ID: 12161284
    [Abstract] [Full Text] [Related]

  • 6. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.
    Selenko-Gebauer N, Majdic O, Szekeres A, Höfler G, Guthann E, Korthäuer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, Knapp W, Stöckl J.
    J Immunol; 2003 Apr 01; 170(7):3637-44. PubMed ID: 12646628
    [Abstract] [Full Text] [Related]

  • 7. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2004 Oct 01; 155(1-2):172-82. PubMed ID: 15342209
    [Abstract] [Full Text] [Related]

  • 8. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
    Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FB, Coyle AJ, Hoogsteden HC, Lambrecht BN.
    Eur J Immunol; 2006 Sep 01; 36(9):2472-82. PubMed ID: 16917960
    [Abstract] [Full Text] [Related]

  • 9. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
    Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ.
    Nat Immunol; 2001 Mar 01; 2(3):261-8. PubMed ID: 11224527
    [Abstract] [Full Text] [Related]

  • 10. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
    Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Khan N, Veldman G, Jacobs KA, Valge-Archer VE, Collins M, Carreno BM.
    J Immunol; 2003 Jan 15; 170(2):711-8. PubMed ID: 12517932
    [Abstract] [Full Text] [Related]

  • 11. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.
    Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, Fukushima T, Akiba H, Yagita H, Okumura K, Machida U, Iwai H, Azuma M, Chen L, Watanabe M.
    J Immunol; 2003 Oct 15; 171(8):4156-63. PubMed ID: 14530338
    [Abstract] [Full Text] [Related]

  • 12. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
    Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, Azuma M, Yagita H, Sayegh MH, Khoury SJ.
    J Immunol; 2006 Mar 15; 176(6):3480-9. PubMed ID: 16517716
    [Abstract] [Full Text] [Related]

  • 13. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells.
    Chen C, Qu QX, Huang JA, Zhu YB, Ge Y, Wang Q, Zhang XG.
    Immunobiology; 2007 Mar 15; 212(3):159-65. PubMed ID: 17412283
    [Abstract] [Full Text] [Related]

  • 14. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
    Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS.
    J Immunol; 2008 Nov 15; 181(10):6738-46. PubMed ID: 18981091
    [Abstract] [Full Text] [Related]

  • 15. PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.
    Peña-Cruz V, McDonough SM, Diaz-Griffero F, Crum CP, Carrasco RD, Freeman GJ.
    J Invest Dermatol; 2010 Sep 15; 130(9):2222-30. PubMed ID: 20445553
    [Abstract] [Full Text] [Related]

  • 16. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, Azuma M, Sharpe AH, Auchincloss H, Sayegh MH, Najafian N.
    J Immunol; 2005 Jun 01; 174(11):6648-56. PubMed ID: 15905503
    [Abstract] [Full Text] [Related]

  • 17. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL, Li F, Zhao F, Zuo JJ, Deng YQ, Zhang W, Tao ZZ.
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr 07; 55(4):384-390. PubMed ID: 32306637
    [Abstract] [Full Text] [Related]

  • 18. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, Domenig C, Habicht A, Najafian N, Yagita H, Azuma M, Turka LA, Sayegh MH.
    J Immunol; 2005 Mar 15; 174(6):3408-15. PubMed ID: 15749874
    [Abstract] [Full Text] [Related]

  • 19. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
    Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH.
    J Exp Med; 2006 Apr 17; 203(4):883-95. PubMed ID: 16606670
    [Abstract] [Full Text] [Related]

  • 20. Programmed death-1 targeting can promote allograft survival.
    Ozkaynak E, Wang L, Goodearl A, McDonald K, Qin S, O'Keefe T, Duong T, Smith T, Gutierrez-Ramos JC, Rottman JB, Coyle AJ, Hancock WW.
    J Immunol; 2002 Dec 01; 169(11):6546-53. PubMed ID: 12444166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.